In the words
of Edward Kasner and James Newman: «Structural engineers, concerned with the elasticity
of beams, the strength columns, and any
phase of construction where there is shear and stress, find first, second,
third, and fourth derivatives indispensable... «10 As will be noted shortly there is no limit to the number
of a derivative.
Table 1: Selection, Design &
Construction of HSV - based Oncolytic Viruses Table 2: Selection, Design &
Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design &
Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design &
Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design &
Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design &
Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials
of T - Vec Table 8: Clinical Trials
of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials
of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview
of Oncolytic Viruses by Development
Phase & Virus Family Table 14: Profile
of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design
of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications
of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies
of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies
of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies
of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern
of Transgenes in Oncolytic Viruses in Relation to Development
Phase Tables 21a and 21b: Indications and Frquency and Way
of Administration
of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development
of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio
of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests
of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources
of Technology Table 26: Second Generation Oncology Virus Companies and their Sources
of Technology Table 27:
Third Generation Oncology Virus Companies and their Sources
of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources
of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions
Mr. Ebert has extensive experience in many
phases of civil practice, including appeals, in matters involving insurance defense, insurance coverage, bad faith,
third - party liability, self - insured defense, defense
of intentional torts, and
construction, environmental, and commercial litigation.